Regenerative meta-start antibody cocktail therapy Phase 3 clinically used to prevent new crown virus infection.
-
Last Update: 2020-07-29
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
REGN-COV2 consists of two monoclonal antibodies combined with the key receptor binding domain (RBD) of the new coronavirus sting proteinThe RBD binding sites of the two antibodies are different, so the combination can reduce the virus's ability to escape monoantibody therapy by producing genetic mutationsPreclinical research on the two antibodies has been published in the journal ScienceIn Phase 1 clinical trials, an independent data monitoring committee's review of the initial queue of 30 inpatient and non-inpatient COVID-19 patients found that REGN-COV2 showed good safetyThe phase 3 prevention trial, which is being conducted at about 100 research centers and is expected to recruit 2,000 patients in the United States, will assess the status of SARS-CoV-2 infectionThe Phase 2/3 treatment pilot programme was conducted in approximately 150 research centres in the United States, Brazil, Mexico and Chile in patients in hospital (estimated number of participants, 1850) and non-inpatients (estimated number of participants, s.1050), and will evaluate virology and clinical endpoints, with preliminary data expected later this summerAll trials are adaptive and the final number of patients in the group will depend on the progress of the trial and the results of the Phase 2 studyDrGeorge DYancopoulos, Co-founder, President and Chief Scientific Officer of Regeneration, said, "We are simultaneously conducting adaptive trials to provide a potential solution to prevent and treat COVID-19 infection as quickly as possible." We are pleased to work with NIAID on REGN-COV2 to seek further ways to stop the spread of the virusReferences: Regeneron Announces Start of REGN-COV Phase2 3 COVID-19 Prevention Trial in The Collaboration with National Institute of Allergy and Post Diseases (NIAID)Retrieved 2020-07-06, from the original title: Prevention of new crown virus infection, regenerative meta-start antibody cocktail therapy Phase 3 clinical trial.
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.